James F. Oliviero III
2023
In 2023, James F. Oliviero III earned a total compensation of $1.6M as President, Chief Executive Officer and Director at Checkpoint Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $286,011 |
|---|---|
| Salary | $635,580 |
| Stock Awards | $720,000 |
| Total | $1,641,591 |
Oliviero received $720K in stock awards, accounting for 44% of the total pay in 2023.
Oliviero also received $286K in non-equity incentive plan and $635.6K in salary.
Rankings
In 2023, James F. Oliviero III's compensation ranked 706th out of 3,006 executives tracked by ExecPay. In other words, Oliviero earned more than 76.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 706 out of 3,006 | 77th |
Division Manufacturing | 402 out of 1,650 | 76th |
Major group Chemicals And Allied Products | 275 out of 918 | 70th |
Industry group Drugs | 269 out of 881 | 70th |
Industry Pharmaceutical Preparations | 174 out of 637 | 73rd |
Source: SEC filing on April 2, 2024.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2023.
2023
Garrett Gray
Checkpoint Therapeutics
Chief Financial Officer
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019